ir.ionispharma.comInvestors & Media | Ionis Pharmaceuticals, Inc.

Investors & Media | Ionis Pharmaceuticals, Inc. Skip to main navigation menu About Ionis Innovation Overview Anisense Technology Optimizing Antisense Pipeline Our Medicines Patients & Community Overview Patient Resources Community Engagement Patient Experiences Investors & media Back to main Overview Newsroom Back to main Investors & Media Press Releases InBriefs Media Center Events Stock Information Back to main Investors & Media Stock Quote & Chart Analyst Coverage Ownership Profile Financials Back to main Investors & Media SEC Filings Annual Reports Governance Back to main Investors & Media Governance Documents Committee Composition Clawback Policy RSU Holdings Guidelines Investor Resources Back to main Investors & Media Investor FAQs Contact Us Careers Overview Working at Ionis Intern Program Post Doctoral Program Follow Us twitter-grey About Ionis Innovation Overview Anisense Technology Optimizing Antisense Pipeline Our Medicines Patients & Community Overview Patient Resources Community Engagement Patient Experiences Investors & media Overview Newsroom Press Releases InBriefs Media Center Stock Information Stock Quote & Chart Analyst Coverage Ownership Profile Financials SEC Filings Annual Reports Governance Governance Documents Committee Composition Clawback Policy RSU Holding Guidelines Investor Resources Investor FAQs Contact Us Events Events Careers Overview Working at Ionis Intern Program Post Doctoral Program Follow Us twitter-grey Investors & Media Overview Newsroom Events Stock Information Financials Governance Investor Resources Investor Email alerts Investor contact D. Wade Walke, Ph.D. 760-603-2331 Email » Media contact Roslyn Patterson 760-603-4679 Email » Company profile Investors & Media Ionis is a sustainably profitable, multi-product company with a pipeline of more than 40 first-in-class and/or best-in-class medicines. We have created an efficient, broadly applicable, proprietary technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective or ever existed. We continue to lead the way in RNA-targeted drug discovery and development of transformational medicines. See our company fact sheet » -- View stock performance » Recent news » Events » Company presentation » Copyright West LLC. Minimum 15 minutes delayed. “Because we can transform the treatment of a disease, we will always choose YES. No patient ever got better with a no.” You are now leaving www.ionispharma.com to visit www.spinraza.com. Continue to site » Cancel The Ionis advantage Going where others can’t or won’t For 30 years we have been the leading innovator in RNA-targeted therapeutics, creating substantial value for patients and shareholders. We pioneered the development of a novel more efficient drug discovery platform and have created medicines that span multiple therapeutic areas, routes of administration and diverse patient populations. With approved first-in-class medicines for SMA, hATTR, and FCS, and a pipeline of novel therapies addressing previously undruggable targets in cardiometabolic diseases, neurodegenerative diseases, cancer, severe and rare diseases, Ionis is truly a force for life. A strong and flexible foundation Because antisense therapies can treat the rarest of diseases as well as those that affect millions of people, we pursue a development path for each therapy that we believe will most efficiently deliver it to patients, whether through partnerships or one of our commercial affiliates. With a strong foundation based on commercial and R&D revenue, Ionis is in a strong financial position that allows us to continue to invest in commercializing our medicines, advancing and expanding our pipeline and continuing to optimize our technology to further drive our competitive advantage. Unrivaled efficiency in drug discovery through clinical proof of value Today, antisense technology delivers one of the most efficient routes from gene to target to patient. This efficiency is demonstrated by our high success rate in translating a clinical candidate from discovery stage to clinical development. We average one medicine per 11 employees at Ionis. With world-class scientists dedicated to optimizing our technology, we are experts in identifying which antisense therapies to advance through varying stages of clinical development. Experienced leadership The Ionis management team is one of the longest tenured teams in biotechnology history, with the majority of the leaders working together for more than two decades to deliver on the Ionis vision. Multiple near-term value drivers By the end of 2020, Ionis plans to have over 10 medicines in pivotal clinical studies, with four of those pivotal studies starting in 2019. ©1989 - 2020 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc. Contact Suppliers Legal Notice Privacy policy...